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Abstract
Background: Those affected by advanced fibrotic interstitial lung diseases have limited treatment options and in
the terminal stages, the focus of care is on symptom management. However, quantitatively, little is known about
symptom prevalence. We aimed to determine the prevalence of symptoms in Progressive Idiopathic Fibrotic
Interstitial Lung Disease (PIF-ILD).
Methods: Searches on eight electronic databases including MEDLINE for clinical studies between 1966 and 2015
where the target population was adults with PIF-ILD and for whom the prevalence of symptoms had been
calculated.
Results: A total of 4086 titles were screened for eligibility criteria; 23 studies were included for analysis. The highest
prevalence was that for breathlessness (54–98%) and cough (59–100%) followed by heartburn (25–65%) and
depression (10–49%). The heterogeneity of studies limited their comparability, but many of the symptoms present
in patients with other end-stage disease were also seen in PIF-ILD.
Conclusions: This is the first quantitative review of symptoms in people with Progressive Idiopathic Fibrotic
Interstitial Lung Diseases. Symptoms are common, often multiple and have a comparable prevalence to those
experienced in other advanced diseases. Quantification of these data provides valuable information to inform the
allocation of resources.
Keywords: Pulmonary fibrosis, Symptom prevalence and interstitial lung disease
Background
Patients with Interstitial Lung Disease have a wide range
of diagnoses and prognoses. Many patients can live
many years with their diagnosis and some are responsive
to treatments. However, a subset of patients with Pro-
gressive Idiopathic Fibrotic Interstitial Lung Diseases
(PIF-ILD) such as idiopathic pulmonary fibrosis have a
short disease trajectory and a similar prognosis to people
with lung cancer [1]. The clinical manifestation of ad-
vanced fibrotic Non Specific Interstitial Pneumonia
(NSIP) is similar to IPF [2]. It is important to differenti-
ate NSIP from IPF in the early stages when the disease is
potentially responsive to therapy [2] .However, when the
disease is advanced and irreversible, this becomes less
important and the focus should be on symptom control.
The United Kingdom (UK) End of life care strategy
aimed to promote high quality care for all adults at the
end of life [3]. In addition, the British Thoracic [4] and
NICE idiopathic pulmonary fibrosis guidance [5]
emphasize the importance of a proactive approach in
managing symptoms.
Recent qualitative work in this group has shown un-
controlled symptoms, for example, shortness of breath,
cough and insomnia, which impact on every aspect of
patients and carers lives [6, 7]. However, quantitative
work assessing prevalence of symptoms is limited and
there has been no systematic review of this literature.
Synthesising the quantitative evidence for symptom
prevalence for this group will add to previous qualitative* Correspondence: sabrina.bajwah@kcl.ac.uk
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work, raise awareness of these symptoms and focus clin-
ical intervention.
Methods
Aim
To estimate the symptom prevalence in people with
PIF-ILD.
Design
Systematic review of the literature.
Search strategy
We performed comprehensive searches of databases in-
cluding MEDLINE, Cochrane, EMBASE, Science Citation
Index Expanded (Web of Knowledge), pre-Medline,
CINAHL and PSYCINFO from 1966 to November 2013
using a combination of MESH headings and keywords
(for full search strategy see online Additional file 1 AP-
PENDIX A). In addition, key journals hand searched in-
cluded THORAX, American Journal of Respiratory and
Critical Care Medicine and CHEST (2000 to 2013). The
search was updated to March 2015. Only studies in Eng-
lish or Spanish were included.
Selection
Study population
Published data of adults (≥ 18 years old), with all stages
of the following ILD types: interstitial pulmonary fibrosis
(IPF), nonspecific interstitial pneumonia (NSIP), crypto-
genic fibrosing alveolitis and idiopathic interstitial pneu-
monia from any setting were included.
Studies in which patients had COPD and/or cancer in
addition to PIF-ILD were excluded.
Types of studies included
A scoping search identified a paucity of data. Therefore
all study types reporting quantitative data were included.
Case reports of fewer than five patients were excluded.
Qualitative studies were included if quantitative data
were available for extraction.
Types of outcomes included
Symptoms included were based on a previous systematic
review looking at interventions to improve symptoms
and quality in patients with PIF-ILD [8] and encom-
passed both physical and psychological domains.
Data extraction
One independent reviewer (SC) selected the studies
against the inclusion criteria using the title and, if the
title did not offer enough information, abstracts and/or
full text were read. Data were extracted using a form
that included the main author, year of publication, set-
ting, type and number of participants, disease group,
aims of the study, study design, measurement methods
and prevalence of individual symptoms (See Additional file 2
APPENDIX B).
Data analysis
The Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) Statement checklist for
observational studies [9] was used to appraise each of
the final studies. A palliative symptom grid was used and
the number of patients in each study was calculated for
each of the symptoms. Meta-synthesis and descriptive
statistics were used for analysis and to present the find-
ings. Where appropriate, a meta-analysis of each symp-
tom from multiple studies was conducted using a
random-effects model with inverse-variance weighting.
Symptoms which were reported in only two studies or
less were excluded from the meta-analysis. Heterogen-
eity was also quantified using the I-squared measure
[10]. The confidence intervals are based on exact bino-
mial (Clopper-Pearson) procedures [11]. Meta-analysis
was conducted in Stata (StataCorp 2015) release 14 [12].
Results
Overview of included studies
Twenty-three articles describing symptoms were se-
lected for this review (see Fig. 1) potentially relevant but
excluded studies have been listed separately in Add-
itional file 3 APPENDIX C. Included studies represented
N = 3171 patients from European, Asian, and North and
South American countries, conducted on outpatients at
different disease stages; four studies included patients
with end-stage disease [13–16]. The mean age across all
studies varied between the fifth and sixth decade of life,
and one study included patients older than 65 years [17].
Overall, studies found prognosis ranged between 12.9 to
46 months from time of diagnosis.
Study designs varied with a variety of retro and pro-
spective designs (Table 1).
Symptom prevalence
Respiratory symptoms such as breathlessness and cough
were measured in 13 studies [14, 15, 17–27]; fatigue and
weight loss in five [18, 19, 21, 24, 28]; digestive tract
symptoms in eight [13–16, 19, 20, 29, 30] sleep disorder
in four [19, 28, 31, 32]; and other symptoms such as pain
and urinary tract disorders in five [19–21, 24, 29]. The
incidence of depression and/or anxiety was calculated in
four studies [19, 33–35]. No studies documented delir-
ium, constipation, halitosis, hemoptysis, hiccups, hyper-
phagia, polydipsia or mouth problems. A summary of
findings is presented in Fig. 2.
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Respiratory symptoms
The overwhelming majority of patients had breathless-
ness (68.2–98%) and cough (59–94%) [14, 15, 17–27].
These were not only common symptoms, but preceded
diagnosis by 6.8 months to 4 years [18]. Only one study
documented breathlessness using the modified Medical
Research Council scale (mMRC) (range 0 to 4) in 45.3%
of the participants [17]. Nearly one in ten (9.3%) had
mMRC grade 4. Severe breathlessness was associated
with poor prognosis and those with mMRC scale score 3
and 4 had a median survival of 0.5 years [17].
Depression
A variety of depression measurement tools were used to
provide prevalence estimates of depression ranking be-
tween 10% [34] and 49.2% [19, 33, 35]. A worse depres-
sion score was found to be associated with reduced
Forced Expiratory Volume (FEV), Forced Vital Capacity
(FVC), gas transfer factor and gas constant, increased
duration of diagnosis, greater number of comorbidities
[33]; worse breathlessness severity, pain severity, sleep
quality, 4-m walk time, grip strength and diffusing cap-
acity of the lung for carbon monoxide (DLco) [35].
The prevalence of anxiety was estimated to be as high
as 58% in one study of health-related quality of life
(HRQoL) and symptom burden [34].
Digestive tract symptoms
Upper gastro-intestinal symptoms are described in IPF
and have been investigated in several studies.
Gastro-oesophageal reflux prevalence was shown in 35.7
to 100% [13–16, 20, 30].
Although in some patients this appeared to be asymp-
tomatic, symptoms were reported by a significant pro-
portion: belching (51%) [29], regurgitation (16–40%)
[13–16, 20, 29], heartburn (29–48%) [13–16, 20, 29],
dysphagia (11–43%) [13, 16, 20, 29, 30], and dysphonia
(11%) [20]. Typical acid reflux symptoms were found
[13–15, 20] and usually related to other causes such as
cough (83% in these studies). A correlation between
cough and acid reflux in the oesophagus was seen in
28% of the episodes of reflux [25]. However, 33% of
those without evidence of dysmotility had at least one
oesophageal symptom [20].
Sleep related symptoms
A relationship between obstructive sleep apnoea and IPF
was observed in a 50 patients study with stable breath-
lessness, which a quarter of participants had an Epworth
sleepiness score higher than 10 representing significant
daytime sleepiness [31]. In one study of 30 patients, the
following sleep related symptoms were reported: insom-
nia (46.6%), snoring (40%), excessive daytime sleepiness
Fig. 1 Pooled estimates of prevalence (proportion) of symptoms- random effects model ES = Estimated proportion
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Table 1 Summary of studies included
Author/
Year
Aim Study Design and
symptom assessment
used
Participants (n) Diagnosis Diagnosis method Baseline
%
predicted
lung
function
mean
(SD)
Symptoms prevalence
Akhtar 2013
[33]
To assess the
presence of
depressive symptoms
Prospective study
Wakefield Self-
assessment of Depres-
sion Inventory score≥
15 screening tool
Outpatients (n
= 118)
IPF High resolution
computed
tomography, Lung
biopsy
Not
available
Depression 49.2%
Alhamad
2008 [18]
Describe the clinical
course and prognosis
of IPF among Middle
Eastern patients, and
to attempt to identify
variables that would
predict prognosis.
Retrospective study
Chart reviews,
telephone interviews
Hospital
patients (n =
61)
IPF ATS/ERS criteria FVC 64.8
(21.6)a
Dyspnoea 93%;
Cough 82%; Weight
loss 12%
Araki 2003
[17]
To investigate the
outcome of IPF in
elderly patients whose
pathological diagnosis
corresponded to usual
interstitial pneumonia
on autopsy findings.
Retrospective study
MRC dyspnoea scale,
medical records
Patients older
than 65y,
based on
histological
findings on
autopsy,
complete
medical
records (n =
86)
UIP, IPF Lung biopsy:
Histological findings
consistent with UIP,
IPF
VC 72.6
(25.2)
DLCO
62.8 (30.1)
Dyspnoea 54.7%
Cough 93.2%
Bajwah
2012 [19]
To compare the
palliative care needs,
treatments, and end-
of-life preferences of
PIF-ILD patients
Retrospective study
Medical records
Outpatients
Hospital; Ages
37–99 (n = 45)
PIF-ILD ATS/ERS criteria Not
available
Dyspnoea 93%;
Cough 60%; Fatigue
29%; Insomnia 6%;
Depress ion/anxiety
22%; Anorexia/weight
loss 18%; Chest pain
29%; Generalized pain
9%; Dyspepsia 4%;
Polyuria/polydipsia
4%; Diarrhea 2%;
Dysphagia 2%
Bandeira
2009 [20]
To determine
prevalence of GERD
and to evaluate its
clinical presentation
Prospective study
General questionnaire,
Quality of Life Scale
for Gastroesophageal
Reflux Disease
Outpatients (n
= 28)
IPF ATS/ERS criteria in 11
patients, lung biopsy
17 patients
FVC 66.6
(16.0)
DLCO
44.5 (22.0)
Heartburn 29%;
Nocturnal heartburn
14%; Regurgitation
40%; Nocturnal
regurgitation 18%;
Epigastric pain 18%;
Dysphagia 11%;
Cough 77%;
Nocturnal cough 37%;
Dysphonia 11%; Chest
pain 25%
D’Ovidio
2005 [13]
To determine the
prevalence of
gastroesophageal
reflux in lung
transplant candidates
Interviews and
Esophageal
manometer.
Outpatients (n
= 26)
IPF Not specified FVC
median
(range) 67
(33–96)
DLCO
median
(range) 40
(13–77)
Heartburn
Regurgitation
Dysphagia 65%
Hashemi
Sadraei
2013 [21]
To evaluate the
clinical characteristics
of IPF patients from
The National Research
Institute of
Tuberculosis and Lung
Diseases
Retrospective
descriptive study
Medical records and
interviews
(n = 132) IPF Clinical presentation,
radiographic and or/
pathological findings
ATS criteria
Not
available
Breathlessness 68.2%;
Cough 60.6%; Chest
pain 8.3%; Fatigue
7.6%
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Table 1 Summary of studies included (Continued)
Author/
Year
Aim Study Design and
symptom assessment
used
Participants (n) Diagnosis Diagnosis method Baseline
%
predicted
lung
function
mean
(SD)
Symptoms prevalence
Hoppo
2012 [14]
To determine the
prevalence of GERD
and assess the
proximity of reflux
events in patients
with histologically
proven IPF
Retrospective study (n = 35) IPF Lung biopsy Not
available
Cough 74%;
Heartburn 25%;
Regurgitation 25%
Jeon 2006
[22]
To investigate the
prognostic factors at
initial presentation
and the causes of
death in Korean
patients with IPF
Retrospective study
Medical records
Outpatients (n
= 88)
IPF Surgical lung biopsy
compatible with UIP,
ATS criteria
FVC 74.0
(19.2)
DLCO
65.2 (21.4)
Exertional dyspnoea
89%
Lancaster
2009 [31]
To analyze obstructive
sleep apnea in
clinically stable
patients with IPF
Epworth sleepiness
scale (ESS) ≥10
consistent with
daytime sleepiness
(n = 35) IPF ATS criteria (2000) FVC 68.8
(13.7)a
Daytime sleepiness
25%
Lindell
2010 [34]
To test the ability of a
complex intervention
(PRISM) to decrease
symptom burden,
stress and improve
HRQoL perceptions of
patients with IPF and
their carers.
Nested mixed method
design (experimental,
qualitative) Beck
Anxiety Inventory,
Beck Depression
Inventory-II
Outpatients (n
= 37)
IPF Biopsy and/or High
resolution computed
tomography
70% FVC
> 55 15%
FVC 50–
55 15%
FVC <
50%
Anxiety 58%
Depression 4 (10%)
Mermigkis
2009 [32]
To describe sleep
quality associated to
daytime
consequences in IPF
Cross-sectional control
study Epworth
Sleepiness Scale
Pittsburgh Sleep
Quality Index
Functional Outcomes
in Sleep Questionnaire
Fatigue Severity Scale
Polysomnography
Interview
Outpatients (n
= 15)
IPF ATS/ERS criteria or
lung biopsy
FVC 77.4
(21.2)
DLCO
56.3 (17.8)
Daytime sleepiness
20%; Snoring 40%;
Insomnia 46.6%;
Witnessed apnoea’s
13.3%
Mermigkis
2007 [28]
To describe the
clinical and
polysomnographic
features of SRBD and
to identify predictors
of OSA in IPF patients
Retrospective study
Cleveland Clinic Sleep
Disorders
Questionnaire,
Epworth Sleepiness
scale,
Polysomnography
Outpatients (n
= 18)
IPF ATS/ERS criteria FVC 65.7
(10.4)
DLCO
49.9 (15.3)
Excessive daytime
sleepiness 77.7%;
Snoring 88%; Daytime
fatigue 61%;
Witnessed apnoea’s
44.4%
Ohno 2007
[23]
Not specified Retrospective Clinical
personal records
(n = 1322)
Patients
covered by
public
insurance
IIP Medical records: 12%
pathological diagnosis
from lung biopsy, rest
clinical findings
(respiratory function
test, images, serology)
Not
available
Cough 94%;
Exertional dyspnoea
98%
Patti 2005
[15]
To determine the
prevalence of GERD,
the clinical
presentation of GERD
and reflux profiles in
patients with IPF
Patients rated severity
of symptoms 5 point
scale (0 = no
symptom to 4 =
disabling symptom)
Outpatients (n
= 18)
IPF Not specified Not
available
Heartburn 55%;
Regurgitation 33%;
Cough 83%
Raghu 2006
[29]
To assess the
prevalence and
clinical symptoms of
GER in patients with
Prospective study
24 h oesophageal pH
probe, oesophageal
Outpatients (n
= 65)
IPF ATS criteria FVC 59.9
(20.0)a
DLCO
Belching 51%;
Heartburn 47%;
Regurgitation 16%;
Abdominal pain 7%;
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Table 1 Summary of studies included (Continued)
Author/
Year
Aim Study Design and
symptom assessment
used
Participants (n) Diagnosis Diagnosis method Baseline
%
predicted
lung
function
mean
(SD)
Symptoms prevalence
IPF and compare
findings to patients
with intractable
asthma manifesting
symptoms of GER.
manometry, symptom
questionnaire form
34.8
(15.7)a
Bloating 27%; Chest
pain 24% Choking
13%; Globus 13%;
Hoarseness 31%;
Liquid dysphagia 7%;
Solid dysphagia 16%;
Odynophagia 4%;
Nausea 13%
Ryerson
2012 [35]
To investigate the
prevalence of clinically
meaningful depress
ion at baseline,
characterize the
association of
depression with
patient and disease
specific variables, and
describe the natural
history of depress ion
over a period of
6 months
Cohort Outpatients
(n=)52
ILD (21
with IPF)
ATS/ERS criteria FVC 74.3
(18.5)
DLCO
50.8 (16.3)
Depression 24%
Schoenheit
2011 [24]
To generate in depth
insights regarding the
patient journey,
including symptoms
triggers to seeking
medical care, referral
patterns, initial
diagnoses, follow up
and current disease
management.
Qualitative Interviews
conducted in the
participants at home
Outpatients (n
= 45)
IPF Physician confirmed
diagnosis
Not
available
Exertional dyspnoea
68%; Cough 59%;
Fatigue 28%; Chest
pain 6%; Weight loss
2%
Sweet 2007
[16]
To determine the
prevalence of distal
and proximal reflux,
the oesophageal
manometric profile
and whether or not
reflux symptoms
could be used to
screen for reflux
Retrospective Study
Standardized
interview with a
physician or
technician. Patients
rated severity of
symptoms 5 point
scale (0 = no
symptom to 4 =
disabling symptom)
Outpatients (n
= 30)
IPF Pathological findings
in 25 patients, ATS/
ERS criteria in 5
patients
Not
available
Heartburn 48%;
Regurgitation 43%;
Dysphagia 30%
Tobin 1998
[25]
To investigate the
possible association of
GER and IPF
Qualitative study
Structured interview
Outpatients (n
= 17)
UIP Lung biopsy
compatible with UIP
DLCO
mean
(range)
35.9 (9–
62)
Cough 100%
Von
Plessen
2003 [26]
To study the
incidence and
prevalence of
physician diagnosed
and hospitalized
cryptogenic fibrosing
alveolitis in a well-
defined adult popula-
tion in Norway
Retrospective study
Registration form,
hospital registers (2
physicians extracted
the information)
Hospital
patients 158
incident cases
(1984–1998)
and 61
prevalent cases
(until 31.12.
1998)
CFA Progressive dyspnoea,
crackles on
auscultation and
bilateral shadowings
on chest X-ray with
no exposure to a
known fibrogenic
agent
83 and
80% of
incident
and
prevalent
cases
TLCO <
80%
predicted
Incident cases
dyspnoea 87%;
Prevalent cases 79%
Aksu 2014
[30]
To investigate the
possibility that IPF is
involved in the
pathogenic of GERD
Prospective study Outpatients (N
= 21)
IPF Pulmonary function
tests (spirometry,
carbon monoxide
diffusion capacity,
FVC 94.9
(11.2)a
TLCO
Reflux symptoms
52.4% Severe
dysphagia 23.8%
Epigastric pain 91%
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(20%), and witnessed apnoea’s (13.3%) [32]. Studies used
variety of outcome measures and showed problems with
daytime fatigue (The Functional Systems Scores (FSS)),
daytime dysfunction (Functional Outcomes of Sleep
Questionnaire (FOSQ)) and poor sleep quality (Pittsburgh
Sleep Quality Index (PSQI)). Patients reported excessive
daytime sleepiness (77.7%), snoring (88%), daytime fatigue
(29%), witnessed apnoeas (44.4%), and insomnia (6–46%)
[19, 28, 31, 32].
Anorexia, weight loss, fatigue
The prevalence of weight loss was estimated as 2–18%
(out of N = 151), and the prevalence of fatigue as 7.6–29%
out of N = 240 [18, 19, 21, 24, 28].
Pain
Non-specified pain was found in 9% of the population,
while chest pain affected 6–29% [19–21, 24, 29]. Two
studies found epigastric pain in 18 and 91% of the popu-
lation [20, 30].
Other symptoms
A prevalence of polyuria/polydipsia prevalence of 4%
was found in one study [19].
Discussion
This is the first systematic review to draw together the
symptom profile of people with PIF-ILD and shows a
wide array of symptoms; comparable with those reported
in other advanced diseases [36] (see Table 2). Breathless-
ness is seen to be a major problem, as prevalent as for
people with COPD and heart disease. Likewise, psycho-
logical problems (depression and anxiety) and insomnia
are prevalent in PIF-ILD. However, given the comparable
high prevalence of both breathlessness, anxiety and sleep
disturbance, the estimate for daytime fatigue was sur-
prisingly low [28]. This may be explained, at least in
part, by the different outcome measures used to assess
sleep quality in the different studies and only one study
accounted for comorbid conditions that might interfere
with sleep quality and quality of life [28].
Two other symptoms stand out as particular problems
for people with PIF-ILD. Firstly, cough is identified as
not only highly prevalent, but also of major significance
in terms of symptom burden, often preceding the diag-
nosis by some time. Secondly, although reports of nau-
sea and vomiting are relatively low, there are significant
problems associated with gastro-intestinal dysmotility
leading to reflux which is likely to aggravate cough and
may be associated with chest/epigastric pain.
Most people with respiratory disease have multiple
co-morbidities which contribute long- term symptoms
[37]. In addition, symptoms do not occur in isolation
with demonstrated interactions between many symp-
toms, particularly in lung cancer, where a respiratory
distress cluster of cough, breathlessness and fatigue has
been described [38, 39]. The possibility of specific symp-
tom clusters (clinically observed symptoms associations)
for PIF-ILD which could benefit from a combined symp-
tomatic approach is an area for further research. Know-
ledge of symptom clusters in PIF-ILD may help prompt
clinical investigation of associated symptoms when one
symptom is detected. It is clear from these data that a
single symptom does not occur in isolation. Therefore is
important that symptom assessment in people with
PIF-ILD should focus on all commonly encountered
symptoms and not just breathlessness alone. The signifi-
cant prevalence of anxiety, depression and social isolation
Table 1 Summary of studies included (Continued)
Author/
Year
Aim Study Design and
symptom assessment
used
Participants (n) Diagnosis Diagnosis method Baseline
%
predicted
lung
function
mean
(SD)
Symptoms prevalence
alveolar volume),
study of BAL fluid
(cell count and
lymphocyte subsets,
IL-1 β, TNF-α)
114.1
(16.7)
Huang
2014 [27]
To describe the
clinical features and
prognosis of
microscopic
polyangiitis (MPA)
patients whose initial
respiratory
presentation was
pulmonary fibrosis
Retrospective study
Hospital computer-
assisted search
Hospital
patients MPA
cases (N = 67)
IPF
patients
(N = 19)
Radiological findings
(CT), clinical
manifestations
consistent with UIP
pattern according to
the ATS/ERS/JRS/ALAT
statement 2011
DLCO
range 30–
76
Of IPF patients:
Cough 84.2% Sputum
68.4% Hemoptysis
21.1% Dyspnoea
78.9%
a mean estimates were pooled using the inverse variance weighting method
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as the disease progresses highlights the importance of a
holistic approach embodied by palliative care [6].
Palliative care is the active, total care of people with
advanced, progressive disease [40]. Currently, the vast
majority of palliative care services are provided to pa-
tients with cancer, and access to specialist palliative care
is inconsistent for people with non-malignant disease.
This inequity has been highlighted in the recent NICE
Fig. 2 Pooled estimates of prevalence (proportion) of symptoms- random effects model. ES = Estimated proportion
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guidance for IPF [5]. These stated that the ILD specialist
services should have the skills to assess and manage
most supportive and palliative care needs of the people
under their care. In addition, robust joint working and
pathways of care should also be in place to ensure access
to specialist palliative care for those issues that the ILD
services are unable to address. However, this policy has
been largely unimplemented, and in everyday practice as
currently configured, patients have unmet palliative care
needs [7, 41].
Implications for clinical practice and research
People with PIF-ILD face a sombre prognosis and deteri-
oration in their quality of life with little hope of success-
ful disease modification. Therefore, improvement in
quality of life and palliation of significant symptoms are
crucially important treatment goals [5, 42]. Recognition
that these are prevalent is the first step, the next is to in-
corporate systematic assessment of symptoms and other
palliative care concerns as a routine part of clinical man-
agement by respiratory health professionals. There needs
to be a recognition that other symptoms alongside
breathlessness are present. This is likely to have implica-
tions for education and training needs, extended team
working between respiratory, palliative and primary care,
and service configuration. Validated clinical tools to aid
the clinician to identify and triage symptoms and other
needs are needed for everyday practice and has been
highlighted in the recent NICE quality standard for IPF
[42]. An example of such tool is the recently adapted
and validated Needs Assessment Tool-Interstitial Lung
Disease (NAT-ILD) [43].
Good quality prospective observational studies are
needed to get better estimates of symptom prevalence in
PIF-ILD over the duration of the disease. Such prospect-
ive evaluation would allow investigation of symptoms
not found in this review such as confusion, constipation
and anorexia. In particular, the natural history of symp-
toms as the disease progresses to advanced disease and
end of life along with the impact upon the individual
and their family needs to be described in order to be
able to understand the clinical care needs of this patient
group, inform palliative and supportive care service
planning and to inform study designs for clinical trials of
symptom interventions. To facilitate this, disease sever-
ity with baseline lung function should be published for
all studies.
Symptoms which seem to be of particular concern to
people with PIF-ILD such as cough and gastro-intestinal
dysmotility are under-researched and deserve focus. In
addition, validation of questionnaires to determine the
presence of conditions such as depression and fatigue in
this group would be useful.
Limitations
Only one reviewer screened, selected and extracted data
from the articles included. Those not published in the
English or Spanish language were excluded. Grey litera-
ture was not searched. It was difficult to give an accurate
estimate of symptom prevalence due to the varying qual-
ity of cohort formation, measurement tools and defin-
ition of the symptom in question. Period prevalence
time ranges, varying definitions of symptoms, sample
size proportions and the various different measurement
methods across the studies may all have contributed to
variations in the minimum and maximum prevalence
ranges. Due to the heterogeneity of the study populations
and poor reporting, meta-analyses and sub-analyses by
disease and severity of disease was not possible. Patients
included in these studies had stable disease and were not
receiving oxygen therapy.
Conclusion
This study aimed to determine from existing studies, the
prevalence of a group of symptoms in patients with
PIF-ILD. Symptoms are common, often multiple and
have a comparable prevalence to those experienced by
people with other advanced diseases. Symptoms extend
far beyond respiratory symptoms such as breathlessness
and cough, and include fatigue, sleep disturbance as well
Table 2 Summary of the prevalence of symptoms in Cancer, AIDS, CHF, COPD, ESRD and PIF-ILD (figures for other conditions taken
from Solano et al. 2006 [36])
Symptoms PIF-ILD Cancer AIDS CHF COPD ESRD
Pain 9% 30–94% 30–98% 14–78% 21–77% 11–93%
Depression 10–49.2% 4–80% 17–82% 6–59% 17–77% 2–61%
Anxiety 22–58% 3–74% 13–76% 2–49% 23–53% 7–52%
Fatigue 7.6–29% 23–100% 43–95% 42–82% 32–96% 13–100%
Breathlessness 54.7–98% 16–77% 43–62% 18–88% 56–98% 11–82%
Insomnia 6–46.6% 3–67% 40–74% 36–48% 15–77% 1–83%
Nausea 13% 2–78% 41–57% 2–48% 4% 8–52%
Diarrhea 2% 1–95% 29–53% 12% 8–36%
AIDS Adult Immune Deficiency Syndrome, CHF Chronic Heart Failure, COPD Chronic Obstructive Pulmonary Disease, ESRD End-stage Renal Disease
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as a broad variety of gastrointestinal symptoms. Breath-
lessness and anxiety are as prevalent as in COPD and
heart disease, yet patients rarely have access to breath-
lessness management programs. Cough and gastrointes-
tinal dysmotility appear to be particular issues for people
with PIF-ILD and warrant further work which should in-
clude exploration of a possible PIF-ILD symptom
clusters.
Quantification of these symptoms provide valuable in-
formation to inform the education and training needs of
ILD services to allow routine assessment and manage-
ment by ILD clinicians and appropriate use and alloca-
tion of specialist palliative care resources.
These findings highlight and support the need for a
systematic and validated approach to assessment of
symptoms in every day clinical practice by ILD services.
This would ensure close attention to symptom manage-
ment with appropriate and timely referral to palliative
care services according to need, in order to optimise
quality of life and provide good care during advanced
disease and end of life.
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